SummitTX Capital’s Abivax ABVX Stock Holding History

SummitTX Capital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-56,174	Closed	-$7.58M	–	748
2025 Q4	$7.58M	Buy	56,174 +30,354	+118%	+$3.31M	0.23%	107
2025 Q3	$2.19M	Buy	+25,820	New	+$1.58M	0.09%	237

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

SummitTX Capital's ABVX Position: Q1 2026 in Review

SummitTX Capital sold out of Abivax (ABVX) in Q1 2026, closing a stake of 56,174 shares — an estimated $7.58M sold.

SummitTX Capital first reported a position in ABVX in Q3 2025 and held it in 2 quarters. The position peaked at $7.58M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

SummitTX Capital reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
SummitTX Capital sold 56,174 Abivax shares in Q1 2026, an estimated $7.58M.
SummitTX Capital first reported a position in Abivax in Q3 2025 and held it in 2 quarters.
SummitTX Capital's Abivax position peaked at $7.58M in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.